紫杉醇治疗复发卵巢上皮癌31例临床疗效观察  

A clinical observation of paclitaxel in the treatment of 31 patients with recurrent ovarian epithelial cancer

作　　者：侯宝青[1] 冉立[1] 郭红芸[2] 

机构地区：[1]贵阳医学院附属医院肿瘤科,贵州贵阳550004 [2]山东省肿瘤防治研究院,山东济南250117

出　　处：《现代肿瘤医学》2006年第7期875-877,共3页Journal of Modern Oncology

摘　　要：目的：比较紫杉醇为主的联合化疗在治疗复发卵巢上皮癌时，紫杉醇周疗与月疗不同给药方法的近期疗效、复发后生存时间及毒副作用。方法：回顾性分析1997年1月至2004年12月期间我科用紫杉醇联合化疗的3l例复发性卵巢上皮癌患者。紫杉醇周疗组14例：紫杉醇60mg/m^2静脉滴注每周1次，连续3周为1周期。月疗17例，紫杉醇135mg/m^2静脉滴注3周1次为1周期。铂类等药用法两组相同：顺铂70mg/m^2，或卡铂300mg/m^2或AUC=4—5，或奥沙利铂100mg/m^2静脉滴注d2，均3周重复1次。结果：全组3l例病人均可进行近期疗效评价，总有效率为38．71％。周疗组和月疗组的有效率分别为42．86％（6／14）和35．29％（6／17）。随访的26例病例中，中位生存时间22个月。周疗组和月疗组中位生存时间分别是26．5个月、20个月。紫杉醇的毒副作用以白细胞下降、恶心呕吐、肌肉关节痛、手足麻木、脱发等常见。两组问毒副作用的发生率无明显差异，但周疗组毒副作用发生程度较低。结论：紫杉醇无论对铂类敏感或对铂类耐药的复发卵巢上皮癌病例，均有较高的疗效，是复发卵巢癌的首选药物。紫杉醇周疗与月疗治疗复发卵巢上皮癌的近期疗效相近，而紫杉醇周疗在降低药物毒副作用、改善患者生存质量、延长生存时间方面比紫杉醇月疗更好。Objective：To compare the difference of efficacy and toxicity between weekly and monthly paclitaxel therapy in combination with platinum for treatment of recurrent ovarian epithelial cancer. Methods： Retrospectively analyze the treatment of 31 patients with recurrent ovarian epithelial cancer who was treated with paclitaxel weekly or monthly during the period of 1997,1 - 2004,12 in our hospital. Weekly therapy group： fourteen patients had received weekly therapy with paclitaxel at a dose of 60mg/m^2, day 1 iv infusion, repeated every week, for 3 weeks as 1 course. Monthly therapy group： seventeen patients had been treated with paclitaxel at a close of 135mg/m^2, day 1 iv infusion, repeated every 3 weeks, for 3 weeks as 1 course. Platinum treatment schedules were the same for two groups： cisplatin 70mg/m^2 or carboplatin 300mg/m^2 （or AUC =4 - 5 ） or oxaliplatin 100mg/m^2, day 2 iv infusion, repeated every 3 weeks. Results： The thirty -one patients were all assessed on this study. The overall response rate was 38.71% （ 12/31 ） , 42.86% （6/14） in the weekly group and 35.29% （6/17） in the monthly group respectively, there was no significant difference between the two groups （P 〉 0.05）. In the follow - up 26 cases, the median survival was 22 months, 26.5 months and 20 months in the weekly group and monthly group respectively, there was significant difference between the two groups （ P 〈 0.05 ）. The major toxiticy associated with paclitaxel included neutropenia, vomiting, myalgia, arthralgia, paresthesia and alopecia. There was no significant difference in the incidence of hematologic toxicity and none hematologic toxicity between the two groups. But the degree of toxicity in the weekly group was slight. Conclusion： Paclitaxel has excellent efficacy for treatment of recurrent ovarian epithelial cancer, whether it was platinum sensitive patient or platinum resistant patient. Paclitaxel was predominant for those patients. There was no significant difference in the response rate b

关 键 词：紫杉醇 复发卵巢癌 周疗 月疗 

分 类 号：R737.31[医药卫生—肿瘤]